Evidence map›Paper›PMID 40541245›Full record

ArticleArquivos de neuro-psiquiatria2025

Prognostic factors in ALS: different approaches to the same problem.

Maria Cristina Vázquez, Abayubá Perna, Mariana Legnani, Gustavo Saona

Abstract read
In one paragraph

Article in Arquivos de neuro-psiquiatria, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Maria Cristina VázquezUniversidad de la República, Hospital de Clínicas, Departamento de Neurología, Montevideo, Uruguay.ORCID 0000-0002-0020-8181
Abayubá PernaUniversidad de la República, Hospital de Clínicas, Departamento de Neurología, Montevideo, Uruguay.ORCID 0000-0001-7062-1310
Mariana LegnaniUniversidad de la República, Hospital de Clínicas, Departamento de Neurología, Montevideo, Uruguay.ORCID 0000-0002-4695-4577
Gustavo SaonaInvestigator independiente, Montevideo, Uruguay.ORCID 0000-0003-1329-7475

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The natural history of amyotrophic lateral sclerosis (ALS), the prognoses, and the survival times are fields of considerable interest that are scarcely studied in South American countries.To describe the survival of a representative cohort of Uruguayan ALS patients, and to identify covariates associated with survival using different analyses.Survival was assessed using the Kaplan-Meier method. Different Cox proportional hazards functions were used to identify independent prognostic predictors since the diagnosis: classic, stratified, and truncated.We included 166 definite and probable ALS patients. The median follow-up was of 13.6 years. An analysis was performed according to the recruitment groups: prevalent, exhaustive incident, and non-exhaustive incident cases. The median survival since the diagnosis was longer in the prevalent group (33 months) than in the exhaustive incident (22 months) and non-exhaustive incident (14 months) groups. The median survival time of the entire cohort from onset to death was 37 months and 23 months from the diagnosis. Factors related to survival from diagnosis to death were: age at onset, bulbar region onset, clinical form, and progression rate.The present study described the role of clinical and demographic factors in ALS survival in the Uruguayan population and shed light on differences involving survival models and the temporal bias produced by the lack of precision in determining the onset of the disease.

Indexed as

Amyotrophic Lateral SclerosisAdultAgedAge of OnsetDisease ProgressionFemaleHumansKaplan-Meier EstimateMaleMiddle AgedPrognosisProportional Hazards ModelsTime FactorsUruguay

Identifiers

PMID40541245
PMCPMC12180952

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.